Psilocybin-assisted therapy for depression in people with lung cancer
About this title
Read the official source — NCT07216404This study evaluates the safety and effectiveness of Psilocybin for people with depression.
Understand this study
What is this study about?
This study evaluates the safety and effectiveness of Psilocybin for people with depression.
Who could participate?
This study is for people with depression. Listed age limits: from 18 years. Other eligibility criteria apply.
- Listed locations
- ColumbusSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 10
- Sponsor
- Alan Davis
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug, Other, Procedure
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- Over 18 Years
- Official registry ID
- NCT07216404
- Official title
Show the full official title
Exploring the Safety, Acceptability, and Efficacy of Psilocybin Among Non-Small Cell Lung Cancer Patients With Major Depressive Disorder: A Proof-of-Concept Trial (DREAM LUNG STUDY)
Recruitment & locations
Columbus
Interested in joining this study?
Questions about this study
What is this study about?
This study evaluates the safety and effectiveness of Psilocybin for people with depression.
Who is behind this study?
The study sponsor is Alan Davis.
Does this study involve medication?
Yes. The study involves medication, including Psilocybin.
Who can participate?
This study is for people with depression. Listed age limits: from 18 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
